Game-Changer Alert: New Vaccine Crushes KRAS Mutations — Pancreatic Cancer Patients Stay Cancer-Free Far Longer

Researchers at the University of California, in collaboration with other leading institutions and Elicio Therapeutics, have made significant strides in the fight against some of the deadliest cancers by developing ELI-002 2P, an innovative “off-the-shelf” cancer vaccine specifically designed to target mutations in the KRAS gene—one of the most elusive and common drivers of aggressive tumors.KRAS mutations are particularly notorious in oncology: they fuel approximately 90% of pancreatic ductal adenocarcinomas (the most common form of pancreatic cancer) and around 50% of colorectal cancers, contributing to high relapse rates even after surgery, chemotherapy, and other standard treatments. These mutations have long been considered “undruggable,” making effective therapies a major unmet need in cancer research.

In the phase 1 AMPLIFY-201 trial (a dose-escalation study involving patients with high-risk pancreatic or colorectal cancer who had completed standard treatment but showed signs of minimal residual disease), the vaccine demonstrated highly encouraging results. Out of 25 participants (20 with pancreatic cancer and 5 with colorectal cancer), 21 (85%) mounted a strong immune response specifically against the targeted KRAS mutations (primarily G12D and G12R). This response involved the activation of both CD4+ helper T cells (which coordinate the immune attack) and CD8+ cytotoxic killer T cells (which directly eliminate cancer cells).Even more impressively, many patients developed robust, sustained T-cell immunity, with some showing “antigen spreading”—where the immune system began targeting additional tumor-specific antigens beyond those in the vaccine, potentially broadening its cancer-fighting power. At a median follow-up of about 19.7 months, patients with the strongest mKRAS-specific T-cell responses experienced substantially better outcomes: median relapse-free survival was not reached (meaning many remained cancer-free for far longer), compared to just 3.02 months in those with weaker responses. Overall survival also improved markedly in responders, reaching a median of 28.94 months across the group—far exceeding typical historical benchmarks for these high-risk cases.

Importantly, the vaccine proved safe, with no dose-limiting toxicities reported, paving the way for further development. No participants experienced disease progression during the core study period in ways that undermined the immune benefits observed.Building on this promising early data, researchers have advanced to the expanded ELI-002 7P version, which targets seven common KRAS mutations (G12D, G12R, G12V, G12A, G12C, G12S, and G13D). This broader formulation aims to cover a larger proportion of patients with KRAS-driven cancers. A larger phase 2 trial (AMPLIFY-7P) is currently underway and actively enrolling, focusing on patients with mKRAS-positive pancreatic cancer post-standard therapy. Early immunogenicity data from this ongoing study are already highly positive, with robust T-cell responses observed in nearly all treated patients.This breakthrough highlights a potential paradigm shift in cancer prevention and treatment: using personalized-like immune training (via an off-the-shelf approach) to eliminate lingering cancer cells after initial therapy, delay or prevent recurrence, and improve long-term survival in notoriously hard-to-treat malignancies. While larger trials are needed to confirm efficacy and broader applicability, the results so far offer real hope for transforming outcomes in pancreatic and colorectal cancers, where new options are desperately needed. Ongoing research continues to monitor durability, safety, and clinical impact as this innovative immunotherapy moves forward.